Education
Dr. Zhu completed her Bachelor of Medicine (2011-2016) and M.D. (2016-2019) from the West China School of Medicine, Sichuan University, Chengdu, China. Her academic journey in the field of medicine has paved the way for her expertise in oncology and cancer research. 🎓📚
Experience
Since 2019, Dr. Zhu has been a part of the Department of Radiation Oncology at Jiangsu Cancer Hospital, where she contributes to both clinical care and scientific research. Her leadership in cancer research and clinical innovation is well-recognized within the medical community. 🏥💼
Research Focus
Dr. Zhu’s research primarily revolves around cancer therapeutics, focusing on the AXL receptor tyrosine kinase as an anti-cancer approach, psychological distress in cancer patients, and innovative diagnostic techniques in oncology. She is particularly interested in tumor microenvironment modulation and the application of advanced imaging techniques in cancer treatment. 🔬🧬
Awards and Honors
Throughout her career, Dr. Zhu has been invited to present her work at prestigious international conferences, including the World Congress on Advances in Oncology and the International Symposium on Molecular Medicine. Her research excellence has garnered recognition and invitations to prominent platforms for cancer research and molecular medicine. 🏆🌍
Publication Top Notes
Zhu’s influential article on AXL receptor tyrosine kinase as a promising anti-cancer approach, Molecular Cancer 2019, has reshaped clinical strategies, cited extensively.
Her 2020 study on dual MET/AXL inhibitors in gastric carcinoma, published in MedComm, offers groundbreaking insights into tumor microenvironment modulation.
Zhu’s 2024 research in BMC Psychol on psychological distress in Chinese cancer patients demonstrates the importance of mental health during cancer treatment.
Her 2024 review of circulating microRNAs as diagnostic biomarkers for cervical cancer in Discov Oncol continues to shape diagnostic research in oncology